Trial · NCT03775109
Trial comparisons17
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
1 to 17 of 17
Download this page as JSON| Comparison | Source |
|---|---|
| Canakinumab vs Placebo: Number of Participants Presenting Changes in Steatosis Grade (NAS) From Baseline to Day 28 | Trial comparisons |
| Canakinumab vs Placebo: Number of Patients Presenting Histological Improvement of Alcoholic Hepatitis on Liver Biopsy After 28 Days of Treatment Compared to Baseline. | Trial comparisons |
| Canakinumab vs Placebo: Number of Deaths at Day 90 | Trial comparisons |
| Canakinumab vs Placebo: Number of Patients With Variceal Haemorrhage Over 90 Days | Trial comparisons |
| Canakinumab vs Placebo: Number of Patients Presenting Changes in Presence of Megamitochondria (AHHS) From Baseline to Day 28 | Trial comparisons |
| Canakinumab vs Placebo: Number of Patients With Incidence of Systemic Inflammatory Response Syndrome (SIRS) at Day 28 in Patients Without SIRS at Baseline | Trial comparisons |
| Canakinumab vs Placebo: Number of Patients Presenting Changes in Degree of Neutrophil Infiltration (AHHS) From Baseline to Day 28 | Trial comparisons |
| Canakinumab vs Placebo: Number of Patients With Encephalopathy Over 90 Days | Trial comparisons |
| Canakinumab vs Placebo: Number of Patients With Infection Over 90 Days | Trial comparisons |
| Canakinumab vs Placebo: Number of Patients With Sepsis Over 90 Days | Trial comparisons |
| Canakinumab vs Placebo: Number of Patients With Acute Kidney Injury Over 90 Days | Trial comparisons |
| Canakinumab vs Placebo: Number of Patients With Ascites Over 90 Days | Trial comparisons |
| Canakinumab vs Placebo: Number of Patients With Resolution of Systemic Inflammatory Response Syndrome (SIRS) at Day 28 in Patients With SIRS at Baseline | Trial comparisons |
| Canakinumab vs Placebo: Number of Patients Presenting Changes in Degree of Fibrosis (AHHS) From Baseline to Day 28 | Trial comparisons |
| Canakinumab vs Placebo: deaths from any cause | Trial comparisons |
| Canakinumab vs Placebo: Number of Participants With Treatment-related Adverse Events | Trial comparisons |
| Canakinumab vs Placebo: serious adverse events | Trial comparisons |
trials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03775109/comparisons